Which has higher earnings & valuation, AKTX or GOVX?

Akari Therapeutics has higher earnings, but lower revenue than GeoVax Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A GeoVax Labs $2.49M 0.95 -$21.47M -$19.12 N/A

Is AKTX or GOVX more profitable?

Akari Therapeutics' return on equity of -123.29% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -123.29% -63.01% GeoVax Labs N/A -743.64% -394.74%

Is CMMB or GOVX more profitable?

Chemomab Therapeutics' return on equity of -89.03% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -89.03% -79.68% GeoVax Labs N/A -743.64% -394.74%

Do analysts recommend GOVX or MYNZ?

GeoVax Labs presently has a consensus price target of $150.00, suggesting a potential upside of 21,919.96%. Given GeoVax Labs' higher possible upside, equities analysts plainly believe GeoVax Labs is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher valuation & earnings, GOVX or MYNZ?

GeoVax Labs has higher revenue and earnings than Mainz Biomed. GeoVax Labs is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeoVax Labs $2.49M 0.95 -$21.47M -$19.12 N/A Mainz Biomed $659.94K 15.24 -$21.65M -$65.60 N/A

Is GOVX or MYNZ more profitable?

Mainz Biomed's return on equity of 0.00% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% Mainz Biomed N/A N/A N/A

Is GOVX or BCDA more profitable?

GeoVax Labs' return on equity of -743.64% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% BioCardia N/A -5,456.14% -232.75%

Do analysts rate ASBP or GOVX?

GeoVax Labs has a consensus price target of $150.00, suggesting a potential upside of 21,919.96%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is ASBP or GOVX more profitable?

Aspire Biopharma's return on equity of 0.00% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Aspire Biopharma N/A N/A -398.04% GeoVax Labs N/A -743.64% -394.74%

Does the media prefer ASBP or GOVX?

In the previous week, GeoVax Labs had 9 more articles in the media than Aspire Biopharma. MarketBeat recorded 10 mentions for GeoVax Labs and 1 mentions for Aspire Biopharma. GeoVax Labs' average media sentiment score of 1.35 beat Aspire Biopharma's score of 0.93 indicating that GeoVax Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aspire Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GeoVax Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

GeoVax Labs (GOVX) Competitors

$0.68 -0.02 (-3.05%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$0.68 0.00 (-0.03%)

As of 07/31/2026 05:44 PM Eastern

Compare

GOVX vs. AKTX, CMMB, MYNZ, BCDA, and ASBP

Should you buy GeoVax Labs stock or one of its competitors? MarketBeat compares GeoVax Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GeoVax Labs include Akari Therapeutics (AKTX), Chemomab Therapeutics (CMMB), Mainz Biomed (MYNZ), BioCardia (BCDA), and Aspire Biopharma (ASBP).

How does GeoVax Labs compare to Akari Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

In the previous week, GeoVax Labs had 10 more articles in the media than Akari Therapeutics. MarketBeat recorded 10 mentions for GeoVax Labs and 0 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 1.47 beat GeoVax Labs' score of 1.35 indicating that Akari Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Akari Therapeutics	Positive
GeoVax Labs	Positive

Akari Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.68, meaning that its stock price is 268% more volatile than the broader market.

Akari Therapeutics' return on equity of -123.29% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-123.29%	-63.01%
GeoVax Labs	N/A	-743.64%	-394.74%

Akari Therapeutics presently has a consensus target price of $32.33, suggesting a potential upside of 311.37%. GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 21,919.96%. Given GeoVax Labs' higher possible upside, analysts clearly believe GeoVax Labs is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by company insiders. Comparatively, 0.7% of GeoVax Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Akari Therapeutics has higher earnings, but lower revenue than GeoVax Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
GeoVax Labs	$2.49M	0.95	-$21.47M	-$19.12	N/A

Summary

Akari Therapeutics beats GeoVax Labs on 7 of the 12 factors compared between the two stocks.

How does GeoVax Labs compare to Chemomab Therapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

In the previous week, GeoVax Labs had 10 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 10 mentions for GeoVax Labs and 0 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.89 beat GeoVax Labs' score of 1.35 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Chemomab Therapeutics	Very Positive
GeoVax Labs	Positive

Chemomab Therapeutics currently has a consensus target price of $25.00, suggesting a potential upside of 1,512.90%. GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 21,919.96%. Given GeoVax Labs' higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Chemomab Therapeutics' return on equity of -89.03% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
GeoVax Labs	N/A	-743.64%	-394.74%

Chemomab Therapeutics has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.68, indicating that its share price is 268% more volatile than the broader market.

Chemomab Therapeutics has higher earnings, but lower revenue than GeoVax Labs. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
GeoVax Labs	$2.49M	0.95	-$21.47M	-$19.12	N/A

46.1% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by company insiders. Comparatively, 0.7% of GeoVax Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Chemomab Therapeutics beats GeoVax Labs on 9 of the 14 factors compared between the two stocks.

How does GeoVax Labs compare to Mainz Biomed?

GeoVax Labs (NASDAQ:GOVX) and Mainz Biomed (NASDAQ:MYNZ) are related small-cap companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

In the previous week, GeoVax Labs had 10 more articles in the media than Mainz Biomed. MarketBeat recorded 10 mentions for GeoVax Labs and 0 mentions for Mainz Biomed. GeoVax Labs' average media sentiment score of 1.35 beat Mainz Biomed's score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Overall Sentiment
GeoVax Labs	Positive
Mainz Biomed	Neutral

6.1% of GeoVax Labs shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by company insiders. Comparatively, 18.2% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

GeoVax Labs presently has a consensus price target of $150.00, suggesting a potential upside of 21,919.96%. Given GeoVax Labs' higher possible upside, equities analysts plainly believe GeoVax Labs is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Mainz Biomed's return on equity of 0.00% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
Mainz Biomed	N/A	N/A	N/A

GeoVax Labs has a beta of 3.68, meaning that its share price is 268% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

GeoVax Labs has higher revenue and earnings than Mainz Biomed. GeoVax Labs is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	0.95	-$21.47M	-$19.12	N/A
Mainz Biomed	$659.94K	15.24	-$21.65M	-$65.60	N/A

Summary

GeoVax Labs beats Mainz Biomed on 8 of the 13 factors compared between the two stocks.

How does GeoVax Labs compare to BioCardia?

GeoVax Labs (NASDAQ:GOVX) and BioCardia (NASDAQ:BCDA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

In the previous week, GeoVax Labs had 9 more articles in the media than BioCardia. MarketBeat recorded 10 mentions for GeoVax Labs and 1 mentions for BioCardia. GeoVax Labs' average media sentiment score of 1.35 beat BioCardia's score of 0.22 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Overall Sentiment
GeoVax Labs	Positive
BioCardia	Neutral

BioCardia has lower revenue, but higher earnings than GeoVax Labs. BioCardia is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	0.95	-$21.47M	-$19.12	N/A
BioCardia	$60K	156.32	-$8.23M	-$0.91	N/A

GeoVax Labs has a beta of 3.68, indicating that its stock price is 268% more volatile than the broader market. Comparatively, BioCardia has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

GeoVax Labs' return on equity of -743.64% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
BioCardia	N/A	-5,456.14%	-232.75%

GeoVax Labs currently has a consensus target price of $150.00, suggesting a potential upside of 21,919.96%. BioCardia has a consensus target price of $25.00, suggesting a potential upside of 2,933.24%. Given GeoVax Labs' higher probable upside, equities research analysts clearly believe GeoVax Labs is more favorable than BioCardia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BioCardia	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 0.7% of GeoVax Labs shares are owned by company insiders. Comparatively, 17.4% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

BioCardia beats GeoVax Labs on 8 of the 15 factors compared between the two stocks.

How does GeoVax Labs compare to Aspire Biopharma?

Aspire Biopharma (NASDAQ:ASBP) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

GeoVax Labs has higher revenue and earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	847.60	-$24.48M	-$116.67	N/A
GeoVax Labs	$2.49M	0.95	-$21.47M	-$19.12	N/A

In the previous week, GeoVax Labs had 9 more articles in the media than Aspire Biopharma. MarketBeat recorded 10 mentions for GeoVax Labs and 1 mentions for Aspire Biopharma. GeoVax Labs' average media sentiment score of 1.35 beat Aspire Biopharma's score of 0.93 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aspire Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GeoVax Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aspire Biopharma has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.68, meaning that its stock price is 268% more volatile than the broader market.

Aspire Biopharma's return on equity of 0.00% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-398.04%
GeoVax Labs	N/A	-743.64%	-394.74%

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by company insiders. Comparatively, 0.7% of GeoVax Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

GeoVax Labs has a consensus price target of $150.00, suggesting a potential upside of 21,919.96%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts plainly believe GeoVax Labs is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

GeoVax Labs beats Aspire Biopharma on 10 of the 14 factors compared between the two stocks.

Get GeoVax Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GOVX vs. The Competition

Export

Metric	GeoVax Labs	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.44M	$3.61B	$6.94B	$12.30B
Dividend Yield	N/A	3.77%	2.59%	9.44%
P/E Ratio	-0.04	7.71	280.88	24.54
Price / Sales	0.95	1,260.88	586.87	89.27
Price / Cash	N/A	93.43	71.02	59.62
Price / Book	1.34	16.81	11.07	5.90
Net Income	-$21.47M	-$12.44M	$3.49B	$336.16M
7 Day Performance	-6.84%	-1.42%	-0.24%	0.10%
1 Month Performance	-45.94%	-7.52%	-2.99%	-5.66%
1 Year Performance	-96.24%	48.83%	61.98%	18.85%

GeoVax Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GOVX GeoVax Labs	2.2566 of 5 stars	$0.68 -3.0%	$150.00 +21,920.0%	-96.2%	$2.44M	$2.49M	N/A	10	Positive News Earnings Report Short Interest Increase Analyst Revision Gap Up
AKTX Akari Therapeutics	3.575 of 5 stars	$8.46 -2.8%	$32.33 +282.2%	-81.0%	$9.96M	N/A	N/A	9	Gap Down
CMMB Chemomab Therapeutics	3.1172 of 5 stars	$1.42 +4.4%	$25.00 +1,660.6%	-63.8%	$9.79M	N/A	N/A	20	Positive News
MYNZ Mainz Biomed	N/A	$1.08 -2.7%	N/A	-35.1%	$9.79M	$659.94K	N/A	30
BCDA BioCardia	3.1449 of 5 stars	$0.81 -4.9%	$25.00 +2,992.9%	-61.5%	$9.67M	$60K	N/A	40	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GOVX) was last updated on 8/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeoVax Labs (GOVX) Competitors

GOVX vs. AKTX, CMMB, MYNZ, BCDA, and ASBP

How does GeoVax Labs compare to Akari Therapeutics?

Summary

How does GeoVax Labs compare to Chemomab Therapeutics?

Summary

How does GeoVax Labs compare to Mainz Biomed?

Summary

How does GeoVax Labs compare to BioCardia?

Summary

How does GeoVax Labs compare to Aspire Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX vs. The Competition

GeoVax Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GeoVax Labs (GOVX) Competitors

GOVX vs. AKTX, CMMB, MYNZ, BCDA, and ASBP

How does GeoVax Labs compare to Akari Therapeutics?

Does the media prefer AKTX or GOVX?

Which has more risk and volatility, AKTX or GOVX?

Is AKTX or GOVX more profitable?

Do analysts prefer AKTX or GOVX?

Do institutionals & insiders have more ownership in AKTX or GOVX?

Which has higher earnings & valuation, AKTX or GOVX?

Summary

How does GeoVax Labs compare to Chemomab Therapeutics?

Does the media prefer CMMB or GOVX?

Do analysts recommend CMMB or GOVX?

Is CMMB or GOVX more profitable?

Which has more volatility and risk, CMMB or GOVX?

Which has preferable earnings & valuation, CMMB or GOVX?

Do institutionals & insiders have more ownership in CMMB or GOVX?

Summary

How does GeoVax Labs compare to Mainz Biomed?

Does the media refer more to GOVX or MYNZ?

Do insiders & institutionals hold more shares of GOVX or MYNZ?

Do analysts recommend GOVX or MYNZ?

Is GOVX or MYNZ more profitable?

Which has more risk & volatility, GOVX or MYNZ?

Which has higher valuation & earnings, GOVX or MYNZ?

Summary

How does GeoVax Labs compare to BioCardia?

Does the media favor GOVX or BCDA?

Which has preferable valuation & earnings, GOVX or BCDA?

Which has more volatility & risk, GOVX or BCDA?

Is GOVX or BCDA more profitable?

Do analysts rate GOVX or BCDA?

Do institutionals & insiders hold more shares of GOVX or BCDA?

Summary

How does GeoVax Labs compare to Aspire Biopharma?

Which has preferable earnings and valuation, ASBP or GOVX?

Does the media prefer ASBP or GOVX?

Which has more volatility and risk, ASBP or GOVX?

Is ASBP or GOVX more profitable?

Do institutionals and insiders have more ownership in ASBP or GOVX?

Do analysts rate ASBP or GOVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX vs. The Competition

GeoVax Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools